Open AccessAbstract CT167: First-in-human clinical trial of SC-006, a RNF43 targeted antibody-drug conjugate, as a monotherapy and in combination with budigalimab in patients with advanced colorectal cancer
Author(s) -
Katrina Pedersen,
Amit Mahipal,
Andrea Cercek,
Susanna V. Ulahannan,
Michael Rossi,
Abraham Fong,
Daniel Brickman,
Johanna C. Bendell
Publication year - 2020
Publication title -
cancer research
Language(s) - English
Resource type - Conference proceedings
SCImago Journal Rank - 1.055
H-Index - 84
eISSN - 1538-7445
pISSN - 0008-5472
DOI - 10.1158/1538-7445.am2020-ct167
Subject(s) - medicine , adverse effect , colorectal cancer , cancer , oncology , wnt signaling pathway , clinical trial , gastroenterology , signal transduction , biology , biochemistry